As per reports, Mexico could order an additional 22 million doses of coronavirus vaccine from Johnson & Johnson’s Janssen unit, signed under a memorandum of understanding giving it the option of ordering additional doses, informed the Deputy Health Minister Hugo Lopez-Gatell. Recently, Mexico began its coronavirus clinical trials with Janssen.
“So there we could end up getting up to 22 million more vaccines from Janssen,” Lopez-Gatell, the government’s coronavirus czar informed. “It’s not a contract yet, it’s a letter of intent.”
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.